Abstracts Archive - Page 2336 of 2605 - ACR Meeting Abstracts

Abstract Number: 1431 • 2013 ACR/ARHP Annual Meeting
Algorithms Using Genome-Wide SNP Analysis For Prediction Of Efficacy and Adverse Events Of Abatacept Using Two Population Samples From Multiple Medical Cohorts
Tsukasa Matsubara¹, Satoru Koyano², Keiko Funahashi², Takako Miura¹, Kosuke Okuda¹, Takeshi Nakamura¹, Mitsuyoshi Iwahashi³, Tomomi Tsuru⁴, Shoichi Uchimura⁵, Shigeru Honjo⁶, Akira Sagawa⁷, Takeo Sakurai⁸, Hiroaki Matsuno⁹, Tomomaro Izumihara¹⁰, Eisuke Shono¹¹, Kou Katayama¹², Toyomitsu Tsuchida¹³ and Motohiro Oribe¹⁴, ¹Matsubara Mayflower Hospital, Kato, Japan, ²Research Institute of Joint Diseases, Kobe, Japan, ³Higashi-Hiroshima Memorial Hospital, Higashi-hiroshima, Japan, ⁴PS Clinic, Fukuoka, Japan, ⁵Kanzaki Municipal General Hospital, Kanzaki, Japan, ⁶Honjo Rheumatism Clinic, Takaoka, Japan, ⁷Sagawa Akira Rheumatology Clinic, Sapporo, Japan, ⁸Inoue Hospital, Takasaki, Japan, ⁹Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ¹⁰Izumihara Rheumatic and Medical Clinic, Kagoshima, Japan, ¹¹Shono Rheumatology Clinic, Fukuoka, Japan, ¹²Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, ¹³Tsuchida Clinic, Chiba, Japan, ¹⁴Oribe Rheumatism and Internal Medicine Clinic, Oita, Japan
Background/Purpose: Abatacept (ABT), a CTLA4-Ig fusion protein agent targeted to T-cells, is a relatively new biological agent for RA treatment in Japan. However, there is…
Abstract Number: 1432 • 2013 ACR/ARHP Annual Meeting
The Rate Of Serious Infections Remains Stable In Patients With Multiple Retreatments In Real life : Data From The “Auto Immunity and Rituximab” (AIR) Registry
Jacques-Eric Gottenberg¹, Philippe Ravaud², Patrice Cacoub Sr.³, Thomas Bardin⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Bertrand Godeau⁹, Loic Guillevin¹⁰, Xavier Le Loet¹¹, Eric Hachulla¹², Thierry Schaeverbeke¹³, Jean Sibilia¹⁴, Isabelle Pane¹⁵, Gabriel Baron¹⁶ and Xavier Mariette¹⁷, ¹Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ³Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France, ⁴Rhumatology Departement, Hôpital Lariboisière, Paris, France, ⁵Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France, ⁶Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁷Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁸Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁹Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ¹⁰Department of Internal Medicine,, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹¹Rheumatology Department, CHU of ROUEN, Rouen, France, ¹²Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹³Rhumatology departement, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁴Rhumatologie, CHU Hautepierre, Strasbourg, France, ¹⁵Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁶Epidemiology & Clinical Research, Groupe Hospitalier Bichat-Claude Bernard, Paris, France, ¹⁷Rheumatology Departement, Bicêtre University Hospital, Paris, France
Background/Purpose: Serious infections in patients with rheumatoid arthritis (RA) treated with rituximab (RTX) are slightly more frequent in common practice than in clinical trials. Morevover,…
Abstract Number: 1433 • 2013 ACR/ARHP Annual Meeting
Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis
Edward Keystone¹, MC Genovese², Peter Taylor³, Baojin Zhu⁴, Scott D. Beattie⁴, Stephanie de Bono⁴, Terence Rooney⁴, Douglas E. Schlichting⁴ and William Macias⁴, ¹University of Toronto, Toronto, ON, Canada, ²Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ³NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib, an oral inhibitor of JAK1 and JAK2 activity, was investigated as treatment for patients with moderately to severely active RA despite use…
Abstract Number: 1434 • 2013 ACR/ARHP Annual Meeting
Assessing Janus Kinase inhibitor’s Place In Therapy In Established Rheumatoid Arthritis Patients – From a Simplified Indirect Comparison Versus Tumor Necrosis Factor Inhibitors To a Bayesian Probability Of Response – The Value Of Transparency
Michael P. Ingham¹, Paul Song², Shannon Cartier³, Karin Lawson-Remer² and Erin Murray², ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Doctor Evidence LLC, Santa Monica, CA, ³Optum, Eden Prairie, MN
Background/Purpose: Bayesian style network meta-analyses and mixed treatment comparisons help address potential bias from effect modifying trial covariates within indirect comparisons and are theoretically easier…
Abstract Number: 1435 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of TNF-á Inhibitor Therapy Does Not Differ Between Elderly and Younger Patients With Rheumatoid Arthritis: Results From The Corrona Registry
Aviva C. Hopkins¹, Melisa Martinez-Marti¹, George W. Reed², Ping He³, Jeffrey D. Greenberg⁴, Carlos J. Lozada⁵, Ozlem Pala⁶, Joel M. Kremer⁷ and Dimitrios A. Pappas⁸, ¹Division of Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ²CORRONA, Inc., Southborough, MA, ³UMASS Medical School, Worcester, MA, ⁴New York Hospital for Joint Disease, New York, NY, ⁵Dept of Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁶Department of Medicine/Division of Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁷Albany Medical College and The Center for Rheumatology, Albany, NY, ⁸Columbia University, New York, NY
Background/Purpose: Biologics have revolutionized the therapy and prognosis of patients (pts) with Rheumatoid Arthritis (RA). Studies evaluating whether the effectiveness of TNF-α inhibitor (TNFi) therapy…
Abstract Number: 1436 • 2013 ACR/ARHP Annual Meeting
Early Changes In a Multi-Biomarker Disease Activity Score After Starting Adalimumab Treatment Predict Change In MRI Inflammation At 6 Months
Simon Krabbe¹, R.J. Bolce², Cecilie Heegaard Brahe³, Uffe Møller Døhn³, Scott Cruickshank⁴, Bo J. Ejbjerg⁵, Merete L. Hetland³, E.H. Sasso², D. Chernoff⁶, Michael Sejer Hansen⁷, Lene Surland Knudsen⁸, Annette Hansen⁹, Ole Rintek Madsen⁹, Maria Hasselquist¹⁰, Jakob M. Møller¹¹ and Mikkel Østergaard³, ¹Department of Rheumatology, Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ⁴Scott Cruickshank and Associates, Inc., Santa Barbara, CA, ⁵Slagelse Sygehus, Slagelse, Denmark, ⁶Crescendo Bioscience, Inc., South San Francisco, CA, ⁷Gildhøj Privathospital, Copenhagen, Denmark, ⁸Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, ⁹Copenhagen University Hospital Gentofte, Copenhagen, Denmark, ¹⁰Copenhagen University Hospital Herlev, Copenhagen, Denmark, ¹¹Department of Radiology, Copenhagen University Hospital Herlev, Copenhagen, Denmark
Background/Purpose: A multi-biomarker disease activity (MBDA) score has been validated as a measure of disease activity in rheumatoid arthritis. This study aimed to see if…
Abstract Number: 1397 • 2013 ACR/ARHP Annual Meeting
Changes In MMP In Fibroblast-Like Synoviocytes Following Adipogenesis
Satoshi Yamasaki, Kazuhiko Kumagai, Kouji Endo, Takaki Nojima and Eiji Sugiyama, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: Fibroblast-like synovial cells (FLS) play important roles in the disease progression of RA. FLS produce cytokines and chemokines that contribute to chronic inflammation…
Abstract Number: 1398 • 2013 ACR/ARHP Annual Meeting
Comparison Of Atherogenicity Of Plasma From Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Beenish Hafiz¹, Iryna Voloshyna², Michael J. Littlefield², Steven E. Carsons³, Elise Belilos¹, Kristina Belostocki¹, Lois A. Bonetti⁴, Gary C. Rosenblum¹ and Allison B. Reiss², ¹Rheumatology, Winthrop University Hospital, Mineola, NY, ²Medicine, Winthrop University Hospital, Mineola, NY, ³Div of Rheumatology, Winthrop University Hospital, Mineola, NY, ⁴Rheum & Immun, Winthrop University Hospital, Mineola, NY
Background/Purpose: Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are immune mediated inflammatory disorders linked to increased risk of cardiovascular disease (CVD), mostly due to accelerated…
Abstract Number: 1399 • 2013 ACR/ARHP Annual Meeting
Citrullinated Proteoglycan (Aggrecan) Present In Human Cartilage Is Recognized By Serum Antibodies From Rheumatoid Arthritis Patients
Timea Ocsko¹, Beata Tryniszewska¹, Andras Vida¹, Janos Gal², Gyorgyi Soos², Zoltan Szekanecz³, Tibor A. Rauch¹, Joshua Jacobs¹, Tibor T. Glant¹ and Katalin Mikecz¹, ¹Orthopedic Surgery, Rush University Medical Center, Chicago, IL, ²Rheumatology, Bacs-Kiskun County Hospital, Kecskemet, Hungary, ³Rheumatology, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary
Background/Purpose: Citrullination is a post-translational protein modification, where arginine (Arg) is converted to citrulline (Cit) by peptidyl arginine deiminases (PADI). The presence of anti-citrullinated protein…
Abstract Number: 1400 • 2013 ACR/ARHP Annual Meeting
Dipeptidyl Peptidase IV (DPP-IV, CD26) Levels In Patients With Rheumatoid Arthritis Treated With Biologic Therapies and Correlation With The Activity Of The Disease
José M. Pego-Reigosa¹, Oscar Cordero², Tania López-González², Coral Mouriño-Rodríguez³, Bruno Aspe⁴, Juan Viñuela-Roldán⁵, Rubén Varela-Calviño⁶, Cristina Calviño⁶, Marina Rodríguez-López⁴, Íñigo Hernández-Rodríguez⁴ and Víctor del Campo-Pérez⁷, ¹Instituto de Investigación Biomédica de Vigo (IBIV), Vigo, Spain, ²Biochemistry and Molecular Biology, Universidade de Santiago de Compostela, Santiago de Compostela, Spain, ³Rheumatology, Meixoeiro Hospital, Vigo, Spain, ⁴Rheumatology, University Hospital Complex of Vigo, Vigo, Spain, ⁵Immunology, University Hospital Complex of Santiago, Santiago de Compostela, Spain, ⁶Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain, ⁷Preventive Medicine and Epidemiology, University Hospital Complex of Vigo, Vigo, Spain
Background/Purpose: Dipeptidyl peptidase IV (DPP-IV, CD26), a protease cleaving N-terminal X-Pro dipeptides from selected proteins including chemokines is expressed both as a soluble form and…
Abstract Number: 1401 • 2013 ACR/ARHP Annual Meeting
Reduced Oral Glucose Tolerance Is Associated With a Lower Risk Of Rheumatoid Arthritis
Carl Turesson¹, Ulf Bergström², Mitra Pikwer², Jan-Åke Nilsson² and Lennart Jacobsson¹, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Studies have demonstrated a negative association between high body mass index (BMI) and development of rheumatoid arthritis (RA) in men, and a neutral or…
Abstract Number: 1402 • 2013 ACR/ARHP Annual Meeting
Regulatory B10 Cells Are Decreased In Patients With Rheumatoid Arthritis and Inversely Correlated With Disease Activity
Claire I. Daien^1,2, Sarah Gailhac³, Thibault Mura⁴, Bernard Combe⁵, Michael Hahne¹ and Jacques Morel⁶, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Igmm UMR3555, CNRS, Montpellier, France, ⁴CIC, Hopital Gui De Chauliac, Montpellier, France, ⁵Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁶Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Regulatory IL-10 producing B cells (B10) have been shown to prevent and cure collagen-induced arthritis in mice. In human, very little is known about…
Abstract Number: 1403 • 2013 ACR/ARHP Annual Meeting
Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2) Is Expressed In a TNF-Dependent Manner In RA Synovial Tissues
Borbala Aradi¹, Masaru Kato¹, Mária Filková², Stephanie Kasper³, Kerstin Klein¹, Michael Bader¹, Michael Scharl³, Beat A Michel⁴, Renate E Gay¹, Edit I Buzas⁵, Steffen Gay¹ and Astrid Jüngel¹, ¹Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ³Division of Gastroenterology and Hepatology, University Hospital Zürich and Zürich Center for Integrative Human Physiology, Zurich, Switzerland, ⁴Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ⁵Semmelweis University, Department of Genetics, Cell- and Immunobiology, Budapest, Hungary
Background/Purpose: Protein Tyrosine Phosphatase Non-receptor Type 2 (PTPN2) is a protein phosphatase that has been associated with the development of autoimmune diseases in GWA studies.…
Abstract Number: 1404 • 2013 ACR/ARHP Annual Meeting
Effects Of Smoking On Joint Physiology In Men and Mice
Caroline Ospelt¹, Giovanni Camici², Anna Engler³, Christoph Kolling⁴, Renate E. Gay⁵, Beat A. Michel⁶ and Steffen Gay¹, ¹Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ²Institute of Physiology, University of Zurich, Zurich, Switzerland, ³Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Schultess Clinic, Zurich, Switzerland, ⁵Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ⁶Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Smoking is a major risk factor for the development of anti-citrullinated protein antibodies positive rheumatoid arthritis (RA) in individuals who carry shared epitope alleles.…
Abstract Number: 1405 • 2013 ACR/ARHP Annual Meeting
Expression Of High Mobility Group Protein B1 and Its Receptors In Heart Of Patients With Coronary Artery Disease With and Without Inflammatory Rheumatic Disease: A Biopsy Study
Mei Zong¹, Ivana Hollan², Huiyuan Xiao³, Cecilia Grundtman⁴, Eva Lindroos⁵, Helena E. Harris⁶, Knut MIkkelsen⁷, Stein E. Rynning⁷, Sven M. Almdahl⁸ and Ingrid E. Lundberg⁹, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ³University of Oxford, Oxford, United Kingdom, ⁴Innsbruck Medical University, Innsbruck, Austria, ⁵Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁶Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁷Feiring Heart Clinic, Feiring, Norway, ⁸Cardiothoracic surgery, University Hospital of North Norway, Tromsø, Norway, ⁹Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Patients with inflammatory rheumatic diseases (IRD) have increased risk of morbidity and mortality in coronary artery disease (CAD) compared to the general population. High…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].